Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42M

Q32 Bio Inc. (NASDAQ: QTTB) (“Q32 Bio”), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, announces the completion of its previously announced merger with Homology Medicines, Inc. (“Homology”). The combined company will operate under the name Q32 Bio, and its shares are expected to begin trading on the Nasdaq Global Market on March 26, 2024, under the ticker symbol “QTTB”. Concurrent with the closing of the merger, Q32 Bio completed a $42 million private placement with a syndicate of existing and new investors.

Read the full article: Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42M //

Source: https://www.prnewswire.com/news-releases/q32-bio-announces-closing-of-merger-with-homology-medicines-and-concurrent-private-placement-of-42-million-302098557.html

Leave a Comment

Your email address will not be published.

Scroll to Top